US 10966950
Use of an RXR agonist in treating HER2+ cancers
granted A61KA61K31/185A61K31/216
Quick answer
US patent 10966950 (Use of an RXR agonist in treating HER2+ cancers) held by The Board of Regents of the University of Texas System expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Apr 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61K, A61K31/185, A61K31/216, A61K31/4709, A61K31/517